Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 8/20 | 0.55 |
| ▸ | MME | P08473 | 1/20 | 0.55 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1258858 | 0.91 | AGTR1 (0.63) | AGTR1MMEAGTR2 | |
| SCHEMBL1258216 | 0.86 | AGTR1 (0.54) | AGTR1MMEAGTR2 | |
| SCHEMBL1257745 | 0.83 | AGTR1 (0.52) | AGTR1MMEAGTR2 | |
| SCHEMBL1258431 | 0.83 | MME (0.36) | AGTR1MME | |
| SCHEMBL1257907 | 0.82 | AGTR1 (0.50) | AGTR1AGTR2 | |
| SCHEMBL3632902 | 0.81 | AGTR1 (0.72) | AGTR1AGTR2 | |
| SCHEMBL3627626 | 0.80 | AGTR1 (0.69) | AGTR1AGTR2 | |
| SCHEMBL21124900 | 0.80 | AGTR1 (0.53) | AGTR1MMEAGTR2 | |
| SCHEMBL21125524 | 0.80 | AGTR1 (0.54) | AGTR1MMEAGTR2 | |
| SCHEMBL1257992 | 0.79 | MME (0.42) | AGTR1MME |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158659-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE, INC. (US) | 2012-04-17 | — | — | US | disclosed |
| US-20110281925-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-11-17 | — | — | US | disclosed |
| US-8013005-B2 | Dual-acting antihypertensive agents | THERAVANCE, INC. (US) | 2011-09-06 | — | — | US | disclosed |
| US-20110092551-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2011-04-21 | — | — | US | disclosed |
| US-7879896-B2 | Dual-acting imidazole antihypertensive agents | THERAVANCE, INC. (US) | 2011-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092551-A1 | DUAL-ACTING IMIDAZOLE ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885MME 13/4885AGTR2 2/4885 |
| US-20110281925-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | AGTR1, AGTR2, REN | AGTR1 1/4885MME 5/4885AGTR2 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.